Cargando…

Pharmacokinetics and safety of deltoid or gluteal injection of aripiprazole lauroxil NanoCrystal(®) Dispersion used for initiation of the long-acting antipsychotic aripiprazole lauroxil

BACKGROUND: Aripiprazole lauroxil (AL), a long-acting injectable antipsychotic for the treatment of schizophrenia in adults, can be started with either 21 days of daily oral aripiprazole supplementation or a 1-day initiation regimen consisting of a single injection of a NanoCrystal(®) Dispersion for...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hard, Marjie L., Wehr, Angela, von Moltke, Lisa, Du, Yangchun, Farwick, Sarah, Walling, David P., Sonnenberg, John
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2019
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6607563/ https://www.ncbi.nlm.nih.gov/pubmed/31308935 http://dx.doi.org/10.1177/2045125319859964

Ejemplares similares

Pharmacokinetic Evaluation of a 1-Day Treatment Initiation Option for Starting Long-Acting Aripiprazole Lauroxil for Schizophrenia
por: Hard, Marjie L., et al.
Publicado: (2018)

Population Pharmacokinetic Analysis and Model-Based Simulations of Aripiprazole for a 1-Day Initiation Regimen for the Long-Acting Antipsychotic Aripiprazole Lauroxil
por: Hard, Marjie L., et al.
Publicado: (2018)

Aripiprazole Lauroxil: Pharmacokinetic Profile of This Long-Acting Injectable Antipsychotic in Persons With Schizophrenia
por: Hard, Marjie L., et al.
Publicado: (2017)

Pharmacokinetics, Safety, and Tolerability of a 2-Month Dose Interval Regimen of the Long-Acting Injectable Antipsychotic Aripiprazole Lauroxil: Results From a 44-Week Phase I Study
por: Weiden, Peter J., et al.
Publicado: (2020)

Biological conversion of aripiprazole lauroxil - An N-acyloxymethyl aripiprazole prodrug
por: Rohde, Morten, et al.
Publicado: (2014)

Pharmacokinetic Profile of a 2-Month Dose Regimen of Aripiprazole Lauroxil: A Phase I Study and a Population Pharmacokinetic Model
por: Hard, Marjie L., et al.
Publicado: (2017)

Aripiprazole Lauroxil, a Novel Injectable Long-Acting Antipsychotic Treatment for Adults with Schizophrenia: A Comprehensive Review
por: Maini, Kunal, et al.
Publicado: (2021)

Long-term effect of aripiprazole lauroxil on health-related quality of life in patients with schizophrenia
por: McEvoy, Joseph P., et al.
Publicado: (2021)

Assessing effectiveness of aripiprazole lauroxil vs placebo for the treatment of schizophrenia using number needed to treat and number needed to harm
por: Citrome, Leslie, et al.
Publicado: (2019)

Aripiprazole lauroxil 2-month formulation with 1-day initiation in patients hospitalized for an acute exacerbation of schizophrenia: exploratory efficacy and patient-reported outcomes in the randomized controlled ALPINE study
por: Nasrallah, Henry A., et al.
Publicado: (2021)

Real-World Outcomes and Costs Following 6 Months of Treatment with the Long-Acting Injectable (LAI) Aripiprazole Lauroxil for the Treatment of Schizophrenia
por: Lauriello, John, et al.
Publicado: (2021)

Long-acting formulations delivering aripiprazole: beyond single-value characterizations of steady-state pharmacokinetics
por: McConnell, Scott A, et al.
Publicado: (2017)

Aripiprazole Once-Monthly 400 mg: Comparison of Pharmacokinetics, Tolerability, and Safety of Deltoid Versus Gluteal Administration
por: Raoufinia, Arash, et al.
Publicado: (2017)

TARC: Turkish aripiprazole consensus report- Aripiprazole use and switching from other antipsychotics to aripiprazole- consensus recommendations by a Turkish multidisciplinary panel
por: Veznedaroglu, Baybars, et al.
Publicado: (2018)

Antipsychotic treatments for the elderly: efficacy and safety of aripiprazole
por: Kohen, Izchak, et al.
Publicado: (2010)

Acceptance of the Deltoid Muscle Injection of Aripiprazole Long-acting Injectable in the Patients with Schizophrenia
por: Kamei, Hiroyuki, et al.
Publicado: (2020)

Reversal of symptomatic antipsychotic-induced hyperprolactinemia with addition of aripiprazole
por: Kotorki, Paraskevi, et al.
Publicado: (2010)

Successful treatment of a prolactinoma with the antipsychotic drug aripiprazole
por: Bakker, Ilse C A, et al.
Publicado: (2016)

Add-on Aripiprazole for Atypical Antipsychotic-induced, Clinically Significant Hyperprolactinemia
por: Raveendranthan, Dhanya, et al.
Publicado: (2018)

Chlorine Atoms of an Aripiprazole Molecule Control the Geometry and Motion of Aripiprazole and Deschloro-aripiprazole in Subdomain IIIA of Human Serum Albumin
por: Kawai, Akito, et al.
Publicado: (2022)

New Cocrystals of Antipsychotic Drug Aripiprazole: Decreasing the Dissolution through Cocrystallization
por: Liu, Wenwen, et al.
Publicado: (2021)

Antipsychotic Drug Aripiprazole Protects Liver Cells from Oxidative Stress
por: Kramar, Barbara, et al.
Publicado: (2022)

Aripiprazole cardiosafety: Is it overestimated?
por: Naguy, Ahmed
Publicado: (2016)

Aripiprazole-induced priapism
por: Trivedi, Satya K., et al.
Publicado: (2016)

A Comment on “Add-on Aripiprazole for Atypical Antipsychotic-induced, Clinically Significant Hyperprolactinemia”
por: Naguy, Ahmed
Publicado: (2018)

Aripiprazole for late-life schizophrenia
por: Rado, Jeffrey, et al.
Publicado: (2010)

Tardive Dyskinesia: Treatment with Aripiprazole
por: Kang, Na-Ri, et al.
Publicado: (2011)

Review of depot aripiprazole for schizophrenia
por: Motiwala, Farha Bilal, et al.
Publicado: (2013)

Aripiprazole-induced skin rash
por: Nath, Santanu, et al.
Publicado: (2016)

Tardive Dystonia Related with Aripiprazole
por: Kim, Sunghwan, et al.
Publicado: (2017)

Aripiprazole-induced transient myopia
por: Cumurcu, Tongabay, et al.
Publicado: (2019)

Influence of CYP2D6 Phenotypes on the Pharmacokinetics of Aripiprazole and Dehydro-Aripiprazole Using a Physiologically Based Pharmacokinetic Approach
por: Kneller, Lisa Alina, et al.
Publicado: (2021)

Efficacy and Tolerability of Aripiprazole: A 26-Week Switching Study from Oral Antipsychotics
por: Lee, Jung-Sun, et al.
Publicado: (2010)

Src is the primary target of aripiprazole, an atypical antipsychotic drug, in its anti-tumor action
por: Kim, Mi Seon, et al.
Publicado: (2017)

PM403. Comparison between addition of and switching to aripiprazole for resolving antipsychotic-induced hyperprolactinemia
por: Lee, Jung Suk, et al.
Publicado: (2016)

Behavioral Mechanisms That Depend on Dopamine and Serotonin in Caenorhabditis elegans Interact With the Antipsychotics Risperidone and Aripiprazole
por: Osuna-Luque, Jaime, et al.
Publicado: (2018)

Differences in autonomic nervous system activity between long-acting injectable aripiprazole and oral aripiprazole in schizophrenia
por: Hattori, Saki, et al.
Publicado: (2023)

Serum prolactin levels and sexual dysfunction in patients with schizophrenia treated with antipsychotics: comparison between aripiprazole and other atypical antipsychotics
por: Kirino, Eiji
Publicado: (2017)

Adjunctive Aripiprazole Versus Placebo for Antipsychotic-Induced Hyperprolactinemia: Meta-Analysis of Randomized Controlled Trials
por: Li, Xianbin, et al.
Publicado: (2013)

Update on the Mechanism of Action of Aripiprazole: Translational Insights into Antipsychotic Strategies Beyond Dopamine Receptor Antagonism
por: de Bartolomeis, Andrea, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_3npjlc5suas2n5drii3953f40n